Zacks: Analysts Set $19.00 Price Target for Provention Bio Inc (NASDAQ:PRVB)
Shares of Provention Bio Inc (NASDAQ:PRVB) have received an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.
Brokers have set a twelve-month consensus target price of $19.00 for the company and are expecting that the company will post ($0.31) EPS for the current quarter, according to Zacks. Zacks has also given Provention Bio an industry rank of 62 out of 256 based on the ratings given to related companies.
Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. HC Wainwright reaffirmed a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th. Finally, Chardan Capital assumed coverage on shares of Provention Bio in a report on Monday, June 10th. They issued a “buy” rating and a $20.00 price target for the company.
Provention Bio (NASDAQ:PRVB) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.11). Equities research analysts predict that Provention Bio will post -1.19 earnings per share for the current fiscal year.
In other news, insider Ashleigh Palmer bought 4,000 shares of Provention Bio stock in a transaction on Tuesday, June 18th. The stock was purchased at an average cost of $10.83 per share, with a total value of $43,320.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Anthony Digiandomenico bought 10,000 shares of Provention Bio stock in a transaction on Thursday, June 20th. The shares were purchased at an average cost of $10.96 per share, with a total value of $109,600.00. The disclosure for this purchase can be found here. Insiders bought a total of 39,000 shares of company stock valued at $456,920 over the last ninety days. Company insiders own 19.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its stake in Provention Bio by 26.4% during the 4th quarter. BlackRock Inc. now owns 26,235 shares of the company’s stock valued at $46,000 after purchasing an additional 5,472 shares during the period. Alambic Investment Management L.P. acquired a new position in Provention Bio during the 4th quarter valued at about $29,000. Silverleafe Capital Partners LLC acquired a new position in Provention Bio during the 1st quarter valued at about $46,000. Finally, Lido Advisors LLC acquired a new position in Provention Bio during the 4th quarter valued at about $47,000. 1.77% of the stock is owned by hedge funds and other institutional investors.
Provention Bio Company Profile
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Read More: Tariff
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.